

# Nizoral

ketoconazole

TRADEMARK

## The first oral anti-fungal effective against all pathogenic fungi

### dosage:

vaginal candidosis:	all other superficial and systemic fungal infections:
2 tablets once daily (with food) for 5 days	1 tablet daily (with food) until complete symptomatic and mycological cure is obtained

### PRESCRIBING INFORMATION

Presentation: white, flat, half-scored uncoated tablets marked "Janssen" on one side and k200 on the reverse. Each tablet contains 200 mg ketoconazole. **Uses:** Nizoral is an orally active antimycotic for the treatment in adults, of vaginal candidosis, superficial and systemic mycoses including dermatophyte and yeast infections of the skin, hair and nails, yeast infections of the mouth and GI tract. Also maintenance treatment of systemic mycoses and chronic mucocutaneous candidosis and prophylaxis in "at risk" patients. In children systemic mycoses and severe focal infections where previous topical treatment has failed. **Side-effects, precautions, contra-indications:** contra-indicated in pregnancy. For maximal absorption Nizoral should be taken with meals. The use of agents which reduce gastric acidity (anti-cholinergic drugs, antacids, H<sub>2</sub> blockers) should be avoided and, if indicated, such drugs should be taken not less than two hours after Nizoral. Nausea, skin rash, headache and pruritus may occasionally be observed. Alterations in liver function tests have occurred in patients on ketoconazole, these changes may be transient. Cases of hepatitis have been reported with an incidence of about 1 per 10,000 patients. Some of these may represent an idiosyncratic adverse reaction to the drug. This should be borne in mind in patients on long-term therapy. If a patient develops jaundice or any symptoms suggestive of hepatitis, treatment with ketoconazole should be stopped.

Not all indications are as yet approved in all countries.

Janssen Pharmaceutica  
B-2340 Beerse, Belgium



# ABC OF HYPERTENSION

Hypertension is a common disorder that is easily detected. But it may be deceptively simple: the measurement of blood pressure, interpretation of the results, and the decisions that follow need to be based on a comprehensive knowledge of recent advances.

These illustrated articles on blood pressure measurement, reduction and management have now been collected together in the same format as they appeared in the BMJ to provide a practical guide for general practitioners and others concerned with hypertension.

Price: Inland £3.50;  
Overseas US\$16.00\*  
(Inland £3.00;  
Overseas US\$14.50\* for  
BMA members)


\*including air mail postage

#### Order your copy now

From: The Publisher,  
British Medical Journal,  
BMA House,  
Tavistock Square,  
London WC1H 9JR  
or any leading bookseller

## ABC OF HYPERTENSION

ARTICLES FROM THE BRITISH MEDICAL JOURNAL





## Septrin Assurance

### Prescribing Information

**Indications** Sensitive bacterial infections of the lower respiratory, urinary and genital tracts, sinusitis, otitis media, skin infections, septicaemia, typhoid and paratyphoid fevers, and other infections caused by sensitive organisms.

**Dosage** Septrin Forte Tablets. Adults and children over 12 years: 1 forte tablet twice daily. Maximum dosage for particularly severe infections 1½ forte tablets twice daily. In acute infections Septrin should be given for a minimum of five days or until the patient has been symptom-free for two days.

**Contra-indications** Septrin is contra-indicated in

patients with marked liver parenchymal damage, blood dyscrasias or severe renal insufficiency.

Septrin should not be given to patients hypersensitive to sulphonamides, trimethoprim or co-trimoxazole; should not be given during pregnancy or to neonates.

**Precautions** In renal impairment a reduced dosage is indicated and an adequate urinary output should be maintained. Regular blood counts are necessary whenever long-term therapy is used. Caution is advised in patients with folate deficiency. Care should be taken when giving Septrin to patients receiving oral anticoagulants of the coumarin group, pyrimethamine or sulphonylureas.

**Adverse Reactions** Occasionally, nausea, vomiting, glossitis and skin rashes may occur with normal doses and, very rarely, haematological reactions.

**Presentation** Septrin Forte Tablets each contain 160 mg Trimethoprim BP and 800 mg Sulphamethoxazole BP. PL3/0121.

## Septrin\* Forte 1b.d. co-trimoxazole

Further information is available on request.

Wellcome Medical Division

The Wellcome Foundation Ltd., Crewe, Cheshire



\*Trade Mark

*Published on September 15, 1982...*

# BRITISH NATIONAL FORMULARY

## Number 4 (1982)

Compiled by a panel of experts guided by the Joint Formulary Committee under the chairmanship of Professor O. L. Wade, and published jointly by the British Medical Association and The Pharmaceutical Society of Great Britain.

The aim of the B.N.F. is to encourage effective, economic, and rational prescribing. This edition has been thoroughly revised, and includes virtually all of the four thousand or so preparations available for prescribing in the U.K. A feature is the inclusion of price bands for each preparation, thus enabling the prescriber to compare relative prices of similar preparations. Those preparations which are considered to be less suitable for prescribing are printed in smaller type.

The main part of the book consists of classified notes on drugs and preparations used in the treatment of diseases and conditions. These notes are divided into 15 chapters, each of which is related to a particular system of the human body (cardiovascular, respiratory, etc.) or to another main subject (infections, vaccines, etc.). Each chapter begins with concise

notes for prescribers, intended to provide information to doctors, pharmacists, nurses, etc, and to facilitate the selection of suitable treatment. The notes are followed by details of the relevant drugs and preparations.

Other sections of the B.N.F. aid prescribing in liver diseases and in renal impairment. Appendixes cover drug interactions, intravenous additives, and borderline substances. As in previous editions a Formulary section is included, as is a Dental Practitioners' Formulary. A comprehensive index completes the book.

Because of the introduction of new products and improvement in techniques, and because prices change regularly in an inflationary period, two editions of the new-style B.N.F. will be published in each year.

*Principal contents:* Guidance on prescribing. Emergency treatment of poisoning. Classified notes on drugs and preparations: Gastro-intestinal system; Cardiovascular system; Respiratory system; Central nervous system; Infections; Endocrine system; Obstetrics and gynaecology; Malignant disease and immunosuppression; Nutrition and blood; Musculoskeletal and joint diseases; Eye; Ear, nose and oropharynx; Skin; Immunological products and vaccines; Anaesthesia. Drug interactions. Intravenous additives. Borderline substances. Formulary. Dental Practitioners' Formulary. Index of manufacturers. Index.

The new B.N.F. has been prepared for health-care professionals working within the National Health Service. Prescribing doctors working full-time, whether on a single contract or on a split contract, in the NHS, hospital pharmacies and pharmacies contracted to the NHS will receive copies from their Health Authority or Family Practitioner Committee as appropriate. Medical schools will receive copies every autumn for students who begin their studies in clinical pharmacology and every two years thereafter. Schools of Pharmacy will receive copies for final-year students. Hospital wards and prescribing doctors working part-time in the NHS should have access to reference copies. Additional copies may be purchased from the publishers at £4.50 a copy (which includes postage and packing).

440 pages (paperbound)

September 1982

ISBN: 0 85369 143 6 ..... £4.50  
ISSN: 0260-535X

British Medical Association B.M.A. House, Tavistock Square, London WC1H 9JP  
The Pharmaceutical Press 1 Lambeth High Street, London SE1 7JN

# THE FIRST YEAR OF LIFE


Recent research has vastly improved our understanding of a child's development in the first year of life.

In particular, assessment of normal progress is now much more systematic, so that deviations from the normal are recognised earlier

Dr. Bernard Valman's illustrated account of current methods of examination, assessment and management of the medical problems of early infancy will prove invaluable to all concerned with small babies.

The articles have now been collected into book form in exactly the same format as they appeared in the BMJ.  
Price: Inland £5.00;  
Overseas US\$12.50  
(Inland £4.50;  
Overseas US\$11.25 for  
BMA members)

**Order your copy now**  
From: The Publisher,  
British Medical Journal,  
BMA House,  
Tavistock Square,  
London WC1H 9JR  
*or any leading bookseller*





## NATRILIX ALONE CONTROLS SEVEN OUT OF TEN HYPERTENSIVE PATIENTS FIRST TIME.

### Control first time

At the single dose of one small tablet daily Natrilix alone controls 70-80% of hypertensive patients<sup>1</sup> with a progressive and prolonged action and minimal side effects.

### More acceptable control

With little or no diuretic effect, no need for routine potassium supplements and no absolute contra-indications Natrilix is suitable for a broader spectrum of patients.

**NATRILIX** ■  
indapamide  
One tablet daily

0 Weeks

2

4

6

8

10

12

14

16

#### Prescribing Information

**Name of product.** Natrilix tablets (indapamide hemihydrate).

**Presentation.** Pink biconvex sugar-coated tablets each containing 2.5 mg indapamide hemihydrate. **Uses.** For the treatment of hypertension. Natrilix may be used as sole therapy or combined with other anti-hypertensive agents.

#### Dosage and administration.

**Adults.** The dosage is one tablet, containing 2.5 mg indapamide hemihydrate, daily to be taken in the morning. The action of Natrilix is progressive and the reduction in blood pressure may continue and not reach a maximum until several months after the start of therapy. A

larger dose than 2.5 mg Natrilix daily is not recommended as there is no appreciable additional anti-hypertensive effect but a diuretic effect may become apparent. If a single daily tablet of Natrilix does not achieve sufficient reduction in blood pressure, another anti-hypertensive agent may be added; those which have been used in combination with Natrilix include  $\beta$ -blockers, methyldopa, clonidine and other adrenergic blocking agents. The co-administration of Natrilix with diuretics which may cause hypokalaemia is not recommended. There is no evidence of rebound hypertension on withdrawal of Natrilix.

**Children.** There is no experience of the use of this drug in children. **Contra-indications, warnings, etc.** There are no absolute contraindications to the use of Natrilix but caution should be exercised when prescribing it in cases of severe renal or hepatic impairment. As with all new drugs, the administration of Natrilix should be avoided during pregnancy although no teratological effects have been seen in animals. At doses higher than that recommended, Natrilix has a diuretic effect, therefore it is not recommended to prescribe it with a diuretic agent which may cause hypokalaemia. Also, slight weight loss has been reported in some

patients taking Natrilix. Reported side effects have included nausea and headache, but they are generally uncommon and mild in nature. Serum urate levels may rise slightly but there is no evidence that glucose tolerance is adversely affected.

**Overdosage.** Symptoms of over-dosage would be those associated with a diuretic effect: electrolyte disturbances, hypotension and muscular weakness. Treatment would be symptomatic, directed at correcting the electrolyte abnormalities and gastric lavage or emesis should be considered.

**Pharmaceutical precautions.** Nil.

**Legal category.** Available on prescription only.

**Package quantities.** Cartons of 30 and 60 tablets (containing respectively 2 and 3 push-through blister strips of 15 and 20 tablets).

**Further information.** No interactions have been reported between Natrilix and oral hypoglycaemic agents, anti-coagulants, uricosurics, and anti-inflammatory agents.

**Product licence number.** 0093/0022.

**Price.** Daily cost of treatment: 19.9 p.

**Reference:** 1. A multicentre open trial of indapamide in general practice. Murphy, M.A., Bowker, C.H., Postgraduate Medical Journal, 1981, 57 (Suppl.2), 57-60.

Further information is available on request from  
Servier Laboratories Limited,  
Fulmer Hall, Windmill Road, Fulmer,  
Slough SL3 6HH. Tel: Fulmer 2744.



# In hypertension

## TENORMIN

Atenolol 100mg

### The only beta-blocker to put it all together in one.

Full 24 hour control

One tablet daily

Wide patient  
spectrum

Few CNS  
side-effects

Hydrophilic

Possible  
advantages  
in smokers

Cardioselective

Cardioprotective

### Tenormin fits the profile of the ideal beta-blocker for hypertension.

## TENORMIN

A unique combination of hydrophilicity  
and cardioselectivity

#### Prescribing Notes:

**Dosage:** One tablet daily. **Contraindications:** Heart block. Co-administration with verapamil. **Precautions:** Untreated cardiac failure, bradycardia, renal failure, anaesthesia and pregnancy. **Side Effects:** Coldness of extremities and muscular fatigue. Sleep disturbance rarely seen. Rashes and dry eyes have been reported with beta blockers – consider discontinuance if they occur. Cessation of therapy with beta blockers should be gradual. **Pack size and Basic NHS cost:** 'Tenormin' 28's £7.27. **Product Licence Number:** 'Tenormin' 0029/0122.

Full prescribing information is available on request to the company



Stuart Pharmaceuticals Limited  
Carr House Carrs Road  
Cheadle Cheshire SK8 2EG  
Tenormin is a trade mark for atenolol.

